{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:09:23Z","timestamp":1761523763862,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ejca.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T18:03:19Z","timestamp":1554746599000},"page":"45-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fluoropyrimidines and DPD testing: is there truly an inexorable link?"],"prefix":"10.1016","volume":"113","author":[{"given":"G\u00e9rard","family":"Milano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2019.03.013_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2019.03.013_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2019.03.013_bib3","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2019.03.013_bib4","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2019.03.013_bib5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Canc"},{"issue":"9","key":"10.1016\/j.ejca.2019.03.013_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2019.03.013_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cpt.685","article-title":"Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity","volume":"102","author":"Nie","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ejca.2019.03.013_bib8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.03.013_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2019.03.013_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2019.03.013_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clinbiochem.2018.04.001","article-title":"DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity","volume":"56","author":"Neto","year":"2018","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.ejca.2019.03.013_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/fon.15.276","article-title":"TAS-102: a novel antimetabolite for the 21st century","volume":"12","author":"Uboha","year":"2016","journal-title":"Future Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2019.03.013_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.03.013_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-016-2409-8","article-title":"TAS-102, the first \u201ccardio-gentle\u201d fluoropyrimidine in the colorectal cancer landscape?","volume":"16","author":"Petrelli","year":"2016","journal-title":"BMC Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:23Z","timestamp":1760732663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":14,"alternative-id":["S0959804919302102"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoropyrimidines and DPD testing: is there truly an inexorable link?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}